CS sessions – Guidelines and topics

Guidelines for topics to be discussed and explicated, to clarify expectations and ensure planning for all partners for the new CS and to define the content of the CS dashboard.

- Short introduction CS
- Purpose, overall hypothesis and regulatory questions
- Reflection of available data
- What compounds selected and rationale?
- Clearance studies of compounds for PBPK models.
- In silico contribution to case studies: cheminformatics, PBPK, QVIVE; **who, what, when**.
- Experimental requirements: **who, what, when**.
- Bioinformatics requirements from TempO-Seq samples; **how many** samples, **what model** systems, **when** expected delivery?
- What strategy will be used for data upload and integration, including follow-up (linked to WP2)?
- Timelines of the CS work?
- CS TC planning?
- How will the integrated new data prove the hypothesis?
- What additional scientific questions will be addressed?
- What is the ultimate publication strategy?
- How will the outcome of the CS contribute to the objectives of EU-ToxRisk (e.g. WP11 relevance & objectives listed in the grant agreement)